Olanzapine Depot Approval: What It Means for CMC Teams
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Read the full report on Pharmtech
Story file
How this page works. The Headline Update lists this report from Pharmtech with a short summary and a link to the original. The original reporting and photograph belong to the publisher. Spotted an error in our summary? Tell our corrections desk.
